Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospectiv...

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma  Nature

Tafasitamab + lenalidomide + rituximab approved by Japan’s MHLW for R/R FL - Lymphoma Hub

Tafasitamab + lenalidomide + rituximab approved by Japan’s MHLW for R/R FL  Lymphoma Hub

Epcoritamab Added to Second-Line Lenalidomide/Rituximab Improves Responses in Follicular Lymphoma...

Epcoritamab Added to Second-Line Lenalidomide/Rituximab Improves Responses in Follicular Lymphoma  The ASCO Post

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenal...

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma  Business Wire

Tafasitamab Plus Lenalidomide and Rituximab Nets European Approval in R/R Follicular Lymphoma - O...

Tafasitamab Plus Lenalidomide and Rituximab Nets European Approval in R/R Follicular Lymphoma  OncLive

ASH 2025: Updates in Multiple Myeloma Treatment and Outcomes - Hematology Advisor

ASH 2025: Updates in Multiple Myeloma Treatment and Outcomes  Hematology Advisor

Safety and Efficacy of Direct Oral Anticoagulants as Thromboprophylaxis in Patients With Multiple...

Safety and Efficacy of Direct Oral Anticoagulants as Thromboprophylaxis in Patients With Multiple Myeloma Receiving a Lenalidomide-Based Induction Regimen  Journal of Hematology Oncology Pharmacy

Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line ...

Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line  The American Journal of Managed Care® (AJMC®)

Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma - Targeted Oncology

Sustained Post-ASCT MRD Negativity May Signal Lenalidomide Cessation in Myeloma  Targeted Oncology

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma -...

Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma  Pharmacy Times

Epcoritamab Plus Rituximab/Lenalidomide, Epcoritamab Maintenance Both Deliver Durable Remissions ...

Epcoritamab Plus Rituximab/Lenalidomide, Epcoritamab Maintenance Both Deliver Durable Remissions in First-Line Follicular Lymphoma  OncLive

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma | Leuk...

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma | Leukemia  Nature

Tafasitamab + lenalidomide + rituximab approved by the EC for R/R FL - Lymphoma Hub

Tafasitamab + lenalidomide + rituximab approved by the EC for R/R FL  Lymphoma Hub

Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractor...

Tafasitamab Plus Lenalidomide and Rituximab Significantly Improves Outcomes in Relapsed/Refractory Follicular Lymphoma  The ASCO Post

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: A...

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses | Blood Cancer Journal  Nature

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in ...

Addition of Daratumumab to Lenalidomide Maintenance May Improve MRD-Negative Conversion Rates in Newly Diagnosed Myeloma  OncLive

Epcoritamab in combination with rituximab + lenalidomide approved by the FDA for patients with R/...

Epcoritamab in combination with rituximab + lenalidomide approved by the FDA for patients with R/R FL  Lymphoma Hub

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with h...

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial  Nature

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma - OncLive

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma  OncLive

ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and...

ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/− lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study  Nature

AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM - Hematology A...

AURIGA Study Showed Daratumumab Plus Lenalidomide Increased MRD-Negativity in NDMM  Hematology Advisor

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Dia...

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Diagnosed Myeloma  OncLive

Lenalidomide-induced type II Kounis syndrome: a case report - Frontiers

Lenalidomide-induced type II Kounis syndrome: a case report  Frontiers

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA lon...

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes | Leukemia  Nature

ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma - The ASCO Post

ADAR1 Gene and Response to Lenalidomide in Patients With Multiple Myeloma  The ASCO Post

Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate i...

Combination Elranatamab, Daratumumab, Lenalidomide Shows Promise, Yielding a High Response Rate in Newly Diagnosed MM  ASCO Daily News

FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma - OncLive

FDA Approves Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma  OncLive

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma - OncLive

Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma  OncLive

Dr Yee on Daratumumab/Lenalidomide With Ixazomib/Dexamethasone in Multiple Myeloma - OncLive

Dr Yee on Daratumumab/Lenalidomide With Ixazomib/Dexamethasone in Multiple Myeloma  OncLive

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma - OncLive

Dr Dimopoulos on Elranatamab Plus Daratumumab and Lenalidomide in Myeloma  OncLive

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoc...

Treatment of relapsed or refractory Hodgkin’s lymphoma with lenalidomide combined with PD-1 monoclonal antibody: a case report and literature review  Frontiers

FDA Approves Generic Lenalidomide Capsules in Multiple Strengths - The American Journal of Manage...

FDA Approves Generic Lenalidomide Capsules in Multiple Strengths  The American Journal of Managed Care® (AJMC®)

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly D...

Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly Diagnosed Myeloma  OncLive

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of eld...

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma  Nature

AACR 2025: Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multipl...

AACR 2025: Continuous Subcutaneous Lenalidomide Shows Promise in Reducing Toxicity in R/R Multiple Myeloma  Pharmacy Times

Brazilian Approval Is Sought for Tafasitamab Plus Rituxumab/Lenalidomide in R/R Follicular Lympho...

Brazilian Approval Is Sought for Tafasitamab Plus Rituxumab/Lenalidomide in R/R Follicular Lymphoma  OncLive

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamet...

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GE  The Lancet

Belantamab Mafodotin Triplet Improved Survival, Responses in Patients Refractory to Lenalidomide ...

Belantamab Mafodotin Triplet Improved Survival, Responses in Patients Refractory to Lenalidomide  Pharmacy Times

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Myeloma - Targeted Oncology

Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Myeloma  Targeted Oncology

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor ...

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial  Nature

IMS 2025: Daratumumab Plus Lenalidomide Improves Outcomes in Post-Transplant Maintenance for Myel...

IMS 2025: Daratumumab Plus Lenalidomide Improves Outcomes in Post-Transplant Maintenance for Myeloma  Pharmacy Times

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, New...

Elranatamab Plus Daratumumab/Lenalidomide Generates Early Responses in Transplant-Ineligible, Newly Diagnosed Myeloma  OncLive

Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple ...

Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple Myeloma  Pharmacy Times

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory ...

Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma  OncLive

FDA Approves Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma - Oncology Nursin...

FDA Approves Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma  Oncology Nursing News

Some Frail Myeloma Patients Can Quickly Wean Off Dexamethasone, Study Says - MedPage Today

Some Frail Myeloma Patients Can Quickly Wean Off Dexamethasone, Study Says  MedPage Today

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rit...

From ECHELON-3 to Clinical Practice: Newly Approved Brentuximab Vedotin With Lenalidomide and Rituximab for R/R DLBCL  Pharmacy Times

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myelom...

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myeloma  OncLive

Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and...

Reposition of lenalidomide as a radiation protector based on LINCS gene expression signatures and its preclinical validation  Nature

Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies - CancerNetwork

Lenalidomide/Dasatinib Receive FDA Approval in Hematologic Malignancies  CancerNetwork

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma...

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma  OncLive

Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety - Pharm...

Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety  Pharmacy Times

Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 v...

Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide | Blood Cancer Journal  Nature

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transpla...

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial  Nature

Elranatamab/Daratumumab/Lenalidomide Delivers Strong Response Rates in Transplant-Ineligible Myel...

Elranatamab/Daratumumab/Lenalidomide Delivers Strong Response Rates in Transplant-Ineligible Myeloma  OncLive

Supporting Treatment Decision-Making for Lenalidomide-Refractory Multiple Myeloma Patients Post-D...

Supporting Treatment Decision-Making for Lenalidomide-Refractory Multiple Myeloma Patients Post-DRd in Italy: A Multi-Criteria Decision Framework  EMJ

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma - OncLive

Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma  OncLive

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Fo...

Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in Myeloma Following ASCT  OncLive

ASCO 2025: Adding Elranatamab to Daratumumab, Lenalidomide Induces Durable Responses in Newly Dia...

ASCO 2025: Adding Elranatamab to Daratumumab, Lenalidomide Induces Durable Responses in Newly Diagnosed Multiple Myeloma  Pharmacy Times

China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL - CancerNetwork

China’s NMPA Approves Tafasitamab/Lenalidomide in ASCT-Ineligible DLBCL  CancerNetwork

Dr Falchi on the Efficacy of Fixed-Duration Epcoritamab Plus Lenalidomide and Rituximab in R/R Fo...

Dr Falchi on the Efficacy of Fixed-Duration Epcoritamab Plus Lenalidomide and Rituximab in R/R Follicular Lymphoma  OncLive

Next-Generation Therapies Target High-Risk Smoldering Multiple Myeloma: Paula Rodríguez-Otero, MD...

Next-Generation Therapies Target High-Risk Smoldering Multiple Myeloma: Paula Rodríguez-Otero, MD, PhD  The American Journal of Managed Care® (AJMC®)

How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL? - Lymphom...

How effective is the combination of tafasitamab and lenalidomide in treating R/R DLBCL?  Lymphoma Hub

Tafasitamab in combination with rituximab and lenalidomide approved by the FDA for patients with ...

Tafasitamab in combination with rituximab and lenalidomide approved by the FDA for patients with R/R FL  Lymphoma Hub

Elders With Lenalidomide-Refractory Myeloma May Lack Optimal Treatments - CancerNetwork

Elders With Lenalidomide-Refractory Myeloma May Lack Optimal Treatments  CancerNetwork

Real-World Data Support Rituximab Plus Lenalidomide in NHL - The American Journal of Managed Care...

Real-World Data Support Rituximab Plus Lenalidomide in NHL  The American Journal of Managed Care® (AJMC®)

FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicula...

FDA Approves Monjuvi, Rituximab and Lenalidomide Combination for Relapsed or Refractory Follicular Lymphoma  Managed Healthcare Executive

HRQOL Improved With Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma - CancerNetwork

HRQOL Improved With Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma  CancerNetwork

FDA Approves Brentuximab Vedotin Plus Lenalidomide/Rituximab for R/R LBCL - OncLive

FDA Approves Brentuximab Vedotin Plus Lenalidomide/Rituximab for R/R LBCL  OncLive

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgro...

Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study | Leukemia  Nature

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphom...

Dr Mehta on the FDA Approval of Tafasitamab Plus Rituximab/Lenalidomide in R/R Follicular Lymphoma  OncLive

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL - OncLive

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL  OncLive

Cilta-Cel Significantly Prolongs OS Vs SOC in Lenalidomide-Refractory Multiple Myeloma - OncLive

Cilta-Cel Significantly Prolongs OS Vs SOC in Lenalidomide-Refractory Multiple Myeloma  OncLive

Tafasitamab-Cxix With Rituximab, Lenalidomide Approved by FDA for Relapsed/Refractory Follicular ...

Tafasitamab-Cxix With Rituximab, Lenalidomide Approved by FDA for Relapsed/Refractory Follicular Lymphoma  Pharmacy Times

Alfred L. Garfall, MD, MS, on Ide-Cel and Lenalidomide Maintenance in MM Following Suboptimal ASC...

Alfred L. Garfall, MD, MS, on Ide-Cel and Lenalidomide Maintenance in MM Following Suboptimal ASCT Response  CGTLive®

Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response - On...

Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response  OncLive

Quality by design based ecofriendly HPLC analytical method for simultaneous quantification of era...

Quality by design based ecofriendly HPLC analytical method for simultaneous quantification of erastin and lenalidomide in mesoporous silica nanoparticles  Nature

Brentuximab vedotin in combination with lenalidomide and rituximab receives U.S. FDA approval for...

Brentuximab vedotin in combination with lenalidomide and rituximab receives U.S. FDA approval for the treatment of R/R LBCL  Lymphoma Hub

Tafasitamab in combination with lenalidomide approved by China’s National Medical Products Admini...

Tafasitamab in combination with lenalidomide approved by China’s National Medical Products Administration for adult patients with R/R DLBCL  Lymphoma Hub

Phase III inMIND trial: Efficacy and safety of tafasitamab plus lenalidomide and rituximab for R/...

Phase III inMIND trial: Efficacy and safety of tafasitamab plus lenalidomide and rituximab for R/R FL  Lymphoma Hub

“Icing and the Cherry on Top”: Cilta-Cel Improves Quality of Life in Multiple Myeloma - Oncology ...

“Icing and the Cherry on Top”: Cilta-Cel Improves Quality of Life in Multiple Myeloma  Oncology News Central

FDA Approves Brentuximab Vedotin, Lenalidomide, Rituximab Triplet for R/R LBCL - The American Jou...

FDA Approves Brentuximab Vedotin, Lenalidomide, Rituximab Triplet for R/R LBCL  The American Journal of Managed Care® (AJMC®)

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide - Business Wire

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide  Business Wire

ECHELON-3 trial: Brentuximab vedotin plus lenalidomide and rituximab for patients with R/R DLBCL ...

ECHELON-3 trial: Brentuximab vedotin plus lenalidomide and rituximab for patients with R/R DLBCL  Lymphoma Hub

Lenalidomide-utilizing self-assembled immunogenic cell death-inducing heparin/doxorubicin nanocom...

Lenalidomide-utilizing self-assembled immunogenic cell death-inducing heparin/doxorubicin nanocomplex for anticancer immunotherapy  ScienceDirect.com

Addition of Brentuximab Vedotin to Lenalidomide Rituximab in Relapsed or Refractory DLBCL - The A...

Addition of Brentuximab Vedotin to Lenalidomide Rituximab in Relapsed or Refractory DLBCL  The ASCO Post

Lenalidomide Drug Market to Reach USD 22.04 Bn by 2032 with A Growth Rate of 6.6% – Report by Coh...

Lenalidomide Drug Market to Reach USD 22.04 Bn by 2032 with A Growth Rate of 6.6% – Report by Coherent Market Insights  BioSpace

Brentuximab Vedotin Plus Lenalidomide and Rituximab Receives FDA Approval for Adults With LBCL - ...

Brentuximab Vedotin Plus Lenalidomide and Rituximab Receives FDA Approval for Adults With LBCL  Pharmacy Times

Medicine International - Spandidos Publications

Medicine International  Spandidos Publications

Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q)...

Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q) MDS  OncLive

Dr Querfeld on Durvalumab Plus Lenalidomide vs Durvalumab in Advanced Cutaneous T-Cell Lymphoma -...

Dr Querfeld on Durvalumab Plus Lenalidomide vs Durvalumab in Advanced Cutaneous T-Cell Lymphoma  OncLive

Large Clonal Hematopoiesis Clones Are Associated With Worse Survival Outcomes in MCL - OncLive

Large Clonal Hematopoiesis Clones Are Associated With Worse Survival Outcomes in MCL  OncLive

Darzalex Faspro, Sarclisa Approvals for Multiple Myeloma - National Cancer Institute (.gov)

Darzalex Faspro, Sarclisa Approvals for Multiple Myeloma  National Cancer Institute (.gov)

Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecu...

Lenalidomide-induced pure red cell aplasia is associated with elevated expression of MHC-I molecules on erythrocytes  Nature

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety...

Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database | Blood Cancer Journal  Nature

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma | Blood Cancer...

Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma | Blood Cancer Journal  Nature

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells - Science ...

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells  Science | AAAS

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelod...

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial  Nature

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma:...

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial  Nature

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma - The New England J...

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma  The New England Journal of Medicine